1
Clinical Trials associated with PT-009评价PT010、PT003和PT009对照信必可对中度至极重度COPD患者肺功能的改善的研究
[Translation] A study evaluating PT010, PT003 and PT009 versus Symbicort in improving lung function in patients with moderate to very severe COPD
本研究的总体目的是在中度至极重度慢性阻塞性肺病受试者中进行的多中心、随机、双盲、平行分组、24周、长期给药研究,评估PT010、PT003和PT009与信必可都保作为活性对照药相比的疗效和安全性。
[Translation] The overall objective of this study is to evaluate the efficacy and safety of PT010, PT003, and PT009 compared with Symbicort as an active control in subjects with moderate to very severe COPD in a multicenter, randomized, double-blind, parallel-group, 24-week, long-term dosing study.
100 Clinical Results associated with PT-009
100 Translational Medicine associated with PT-009
100 Patents (Medical) associated with PT-009
100 Deals associated with PT-009